Gene · 51592
Papers2,289
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
161 to 180 of 2,289
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Risk prediction modelling in idiopathic inflammatory myositis-associated interstitial lung disease based on seven factors including serum KL-6 and lung ultrasound B-lines. | Clin Exp Rheumatol | 2025 | 39360376 | PubTator, text mining | PubMed |
| Deleting Trim33 in Myeloid Cells Improves the Efficiency of Radiotherapy through an IFNβ-Dependent Antitumor Immune Response. | Cancer Immunol Res | 2025 | 39325415 | PubTator, text mining | PubMed |
| Validation of the International Myositis Assessment and Clinical Studies Group guideline on cancer risk stratification. | Rheumatology (Oxford) | 2025 | 39287015 | PubTator, text mining | PubMed |
| Serpentine supravenous hyperpigmentation in association with anti-TIF1-gamma antibody-positive myositis. | Int J Dermatol | 2025 | 39219025 | PubTator, text mining | PubMed |
| Poikilodermatomyositis with anti-TIF1-γ antibodies overlap Sjogren's syndrome. | QJM | 2025 | 39213315 | PubTator, text mining | PubMed |
| Coexistence of anti-KS and anti-TIF1-γ antibodies in clinically amyopathic dermatomyositis presenting with rapid progression of interstitial lung disease. | Mod Rheumatol Case Rep | 2025 | 39087260 | PubTator, text mining | PubMed |
| Paraneoplastic dermatomyositis associated with Merkel cell carcinoma. | BMJ Case Rep | 2024 | 42640985 | PubTator, text mining | PubMed |
| Transient negativity for the anti-TIF1γ antibody before treatment in juvenile dermatomyositis. | Rheumatol Adv Pract | 2024 | 39669117 | PubTator, text mining | PubMed |
| Anti-transcription intermediary factor 1 gamma (TIF1-γ) antibody-positive dermatomyositis associated with adenocarcinoma of the ileocecal region: A first case report. | Asian J Surg | 2024 | 39668039 | PubTator, text mining | PubMed |
| Altered metabolic profiles of dermatomyositis with different myositis-specific autoantibodies associated with clinical phenotype. | Front Immunol | 2024 | 39654882 | PubTator, text mining | PubMed |
| Newer Autoantibodies and Laboratory Assessments in Myositis. | Curr Rheumatol Rep | 2024 | 39636383 | PubTator, text mining | PubMed |
| Clinicopathological, Prognostic and Molecular Profile of Salivary Gland Intraductal Carcinoma: A Systematic Review. | Head Neck Pathol | 2024 | 39614957 | PubTator, text mining | PubMed |
| Case Report: IVIG causing bilateral papilledema and increased intracranial hypertension in patients with anti-TIF-1γ antibody-positive JDM. | Front Pediatr | 2024 | 39606693 | PubTator, text mining | PubMed |
| A retrospective study for clinical characteristics of 293 patients with dermatomyositis. | Medicine (Baltimore) | 2024 | 39560562 | PubTator, text mining | PubMed |
| The TRIM33 Bromodomain Recognizes Histone Lysine Lactylation. | ACS Chem Biol | 2024 | 39556662 | PubTator, text mining | PubMed |
| The Immune Modulatory Role of TIF1 Proteins. | Adv Exp Med Biol | 2024 | 39546137 | PubTator, text mining | PubMed |
Comparison of Lineblot and Immunoprecipitation Methods in the Detection of Myositis-Specific and Myositis-Associated Antibodies in Patients with Idiopathic Inflammatory Myopathies: Consistency with Clinical Diagnoses. | Diagnostics (Basel) | 2024 | 39410596 | PubTator, text mining | PubMed |
| TRIM33 promotes glycolysis through regulating P53 K48-linked ubiquitination to promote esophageal squamous cell carcinoma growth. | Cell Death Dis | 2024 | 39389957 | PubTator, text mining | PubMed |
| The Relationship Between Anti-Cell Division Cycle and Apoptosis Regulator 1 Autoantibodies, Anti-Sp4 Autoantibodies, and Cancer in Anti-Transcription Intermediary Factor 1γ-Positive Dermatomyositis. | ACR Open Rheumatol | 2024 | 39370373 | PubTator, text mining | PubMed |
| Increase in Mitochondrial Mass of Lymphocyte Subsets in Anti-MDA5 and TIF1-γ-Positive Dermatomyositis Patients. | Immunol Invest | 2024 | 39291775 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/51592/papers?page=9